JP2018109064A - Alternative formulations for tnfr:fc fusion polypeptides - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide stable aqueous pharmaceutical compositions that are suitable for storage of TNFR:Fc-containing polypeptides, can be prepared completely free of (completely eliminating) arginine and cysteine, and are highly stable at high temperatures.SOLUTION: An aqueous composition comprises: an isolated polypeptide that is an extracellular ligand-binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of a human IgG1; a salt present at a concentration between 80 mM and 130 mM; an aqueous buffer that is sodium and/or potassium phosphate buffer and is present at a concentration between 20 mM and 30 mM; and an excipient that is sucrose and is present at a concentration between 34 mg/mL and 80 mg/mL. The aqueous composition is characterized in that neither arginine nor cysteine is present in the composition.SELECTED DRAWING: None

Description

  The present invention relates to a stable aqueous pharmaceutical composition that does not contain (removed) some selected amino acids suitable for storage of polypeptides containing TNFR: Fc.

  The therapeutic polypeptide formulation is stored until use in most cases. However, polypeptides are unstable when stored in aqueous form for extended periods of time, particularly in the absence of stabilizers such as arginine. An alternative to relying on aqueous storage is the preparation of the polypeptide in lyophilized form, but reconstitution of the dried polypeptide often results in aggregation or denaturation. This polypeptide aggregation is undesirable because it can produce immunogenicity.

  A commercially available soluble form of TNF (tumor necrosis factor) receptor (TNFR: Fc) fused to the Fc domain is known as etanercept. Etanercept (trade name ENBREL®) prevents tumor necrosis factor (TNF) by acting as a TNF inhibitor. This dimeric fusion polypeptide consisting of the extracellular ligand-binding portion of the human 75 kDa (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1 is currently used to prevent L-arginine and And / or L-cysteine is used as an aggregation inhibitor (see Patent Document 1).

  On the other hand, arginine can cause serious side effects in some people. Stomach discomfort, including severe allergic reaction called anaphylaxis, and nausea, gastric spasm, or increased frequency of defecation may occur after arginine injection. Other possible side effects include low blood pressure and many chemical and electrolyte changes in the blood, such as high potassium, high chloride, low sodium, low phosphate, high blood urea nitrogen and high creatinine levels. Can be mentioned. Theoretically, arginine can increase the risk of bleeding, increase blood glucose levels, increase potassium levels and exacerbate sickle cell disease symptoms.

  Cysteine is a non-essential amino acid and is closely related to cystine because it consists of two cysteine molecules bound to each other. Cysteine is an unstable nutrient and is easily converted to cystine. Excess cystine in the body can cause cystine storage disease, a strange disease that can cause cystine crystals to form in the body and cause bladder or kidney stones. It is also known that people suffering from diabetes and cystinuria can suffer from side effects from cysteine supplements.

  Patent Document 2 discloses an arginine-free polypeptide-containing composition in which arginine used in the same composition disclosed in Patent Document 1 is replaced with a salt. This salt is 140 mM according to the example presented (see Example 1). No mention is made of stabilization at high temperatures. In fact, the composition disclosed in Patent Document 2 is stored as a liquid or frozen at 2 to 8 ° C.

European Patent No. 1478394 International Publication No. 2013/006454

  The present invention addresses these challenges by providing a new stable liquid formulation that allows storage of TNFR: Fc polypeptides. Surprisingly, by the inventors, the stable aqueous compositions disclosed herein can be prepared without any arginine and cysteine (completely removed) and are extremely stable at high temperatures. It has been observed that

First Aspect of the Invention A first aspect of the invention is an aqueous formulation comprising an isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1. It is based on the finding that a certain amount of salt can lead to increased protein stability at high temperatures above 5 ° C. Furthermore, the salt concentration is selected so as to be close to physiological body salt concentration.

Accordingly, the present invention provides an isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
A salt present at a concentration of 80 mM to 130 mM;
Excipients selected from the group of trehalose and sucrose and combinations thereof;
An aqueous composition, characterized in that neither arginine nor cysteine is present in the composition.

FIG. 4 shows a bar graph showing the relative denaturation temperature found for all samples (T _onset / ° C.) with error bars found using a fluorescence ratio of 330 nm to 310 nm. FIG. 5 shows a bar graph containing measured pH and osmolality at initial time for all formulations. FIG. 5 shows a bar graph containing measured pH and osmolality at initial time for all formulations. Measurement of protein concentration at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (−20 ° C./25° C.), and 3 days with stirring) It is a figure which shows a value (absorbance in 280 nm). Time to 6 months (0, 1 month, 3 months, and 6 months) and conditions (−20 ° C., 2-8 ° C., 25 ° C., 1 time, 2 times, and 4 times freeze / thaw for Formulation F3 It is a figure which shows the measured value (absorbance in 280 nm) of the protein concentration in (-20 degreeC / 25 degreeC). Measurement of turbidity at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (−20 ° C./25° C.), and 3 days with stirring) It is a figure which shows a value (absorbance in 330 nm). Time to 6 months (0, 1 month, 3 months, and 6 months) and conditions (−20 ° C., 2-8 ° C., 25 ° C., 1 time, 2 times, and 4 times freeze / thaw for Formulation F3 It is a figure which shows the measured value (absorbance in 330 nm) of turbidity in (-20 degreeC / 25 degreeC). Times up to 3 months (0, 1 and 3 months) and conditions (−20 ° C., 2 to 2) for formulations F1, F5, F6 and F8 compared to innovators (t = 0 and 3 months, 25 ° C.) It is a figure which shows the measured value (absorbance in 330 nm) in 8 degreeC, 25 degreeC, 1 time, 2 times, and 4 times freeze / thaw (-20 degreeC / 25 degreeC)). All conditions using Standards-Duke Scientific Count Cal: −20 ° C., 25 ° C., 50 ° C., 3 freeze / thaw cycles (−20 ° C./25° C.), and F1 measured in 3 days with stirring, It is a figure which shows the invisible particle | grain analysis by HIAC about F2, F3, and F4 (1, 2, 3, and 4). Freeze / thaw (-20 ° C / 25 ° C at -20 ° C, 2-8 ° C, 25 ° C, 1 ° and 2 times at t = 0, 1 month and 3 months using Standards-Duke Scientific Count Cal. It is a figure which shows the invisible particle | grains analysis by HIAC about the compound F3 measured by x and 2xFzTh). Standards-Duke Scientific Count Cal using Formulas F1, F3, F5, F6 and F8 for t = 0, 1 month and 3 months, and for Formulation F3, t = 6 months, −20 ° C. and 2-8 ° C. It is a figure which shows the invisible particle | grain analysis by HIAC measured at ° C. T = 0, 1 and 3 months for formulations F1, F3, F5, F6 and F8, and t = 6 months for formulation F3, 25 ° C. and −20 ° C. for F1, F3, F5, F6 and F8 It is a figure which shows the invisible particle | grains analysis by HIAC measured by the freezing / thawing (1x, 2x, 4x (1, 2, 4)) in / 25 degreeC. All conditions: using Coomassie at time 0 and 14 days at −20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (−20 ° C./25° C.) and 3 days incubation with agitation It is a figure which shows the dye | stained SDS-PAGE gel. (A) is an F1 sample, (B) is an F2 sample, (C) is an F3 sample, and (D) is an F4 sample. All conditions: stained with Coomassie for Formulation F3 at t = 3 months incubated at −20 ° C., 2-8 ° C., 25 ° C., -20 ° C./25° C. with 2 freeze / thaw cycles It is a figure which shows an SDS-PAGE gel. All conditions: stained with Coomassie for Formulation F3 at t = 6 months incubated at −20 ° C., 2-8 ° C., 25 ° C., −20 ° C./25° C. with 4 freeze / thaw cycles It is a figure which shows an SDS-PAGE gel. Figure 2 shows an SDS-PAGE gel stained with Coomassie for Formulations F5, F6 and F7 and innovator (control) after a single freeze / thaw at t = 0 and -20 ° C / 25 ° C conditions. is there. Figure 5 shows an SDS-PAGE gel stained with Coomassie for Formulations F8, F9 and F1, and innovator (control) after a single freeze / thaw at t = 0 and -20 ° C / 25 ° C conditions. is there. SDS-stained with Coomassie for Formulations F1 and F5 after two cycles of freeze / thaw at −20 ° C., 2-8 ° C. and 25 ° C. and −20 ° C./25° C. conditions at t = 1 month It is a figure which shows a PAGE gel. SDS-stained with Coomassie for Formulations F1 and F5 after 4 cycles of freeze / thaw at −20 ° C., 2-8 ° C. and 25 ° C., and −20 ° C./25° C. conditions at t = 3 months It is a figure which shows a PAGE gel. SDS-stained with Coomassie for Formulations F6 and F8 after 2 cycles of freeze / thaw at -20 ° C, 2-8 ° C and 25 ° C and -20 ° C / 25 ° C conditions at t = 1 month It is a figure which shows a PAGE gel. SDS-stained with Coomassie for Formulations F6 and F8 after 4 cycles of freeze / thaw at −20 ° C., 2-8 ° C. and 25 ° C. and −20 ° C./25° C. conditions at t = 3 months It is a figure which shows a PAGE gel. FIG. 2 shows size exclusion HPLC chromatograms for all formulations for −20 ° C. conditions at all time points. Peak percentages are measured and shown in the table. FIG. 5 shows size exclusion HPLC chromatograms for all formulations for 25 ° C. conditions at all time points. Peak percentages are measured and shown in the table. FIG. 6 shows size exclusion HPLC chromatograms for all formulations for 50 ° C. conditions at all time points. Peak percentages are measured and shown in the table. FIG. 5 shows size exclusion HPLC chromatograms for all formulations for 3 days conditions with 3 freeze / thaw cycles and agitation. Peak percentages are measured and shown in the table. Size exclusion HPLC chromatograms in formulation F3 for -20 ° C, 2-8 ° C, t = 3 months at 25 ° C, and two freeze / thaw (2xFxTh) conditions at -20 ° C / 25 ° C. FIG. Size exclusion HPLC chromatograms in Formulation F3 for 4 freeze / thaw (2 × FxTh) at −20 ° C., 2-8 ° C., t = 6 months at 25 ° C., and −20 ° C./25° C. conditions. FIG. FIG. 6 shows chromatograms of size exclusion HPLC in formulation F3 at 25 ° C., t = 0, 1 month, 3 months and 6 months, and innovator at t = 3 months and 25 ° C. FIG. 4 shows the size exclusion HPLC chromatogram for formulation F3 at 25 ° C. with t = 0 and 3 months compared to the innovator at t = 0 (control). FIG. 5 shows a size exclusion HPLC chromatogram in a blend innovator at 25 ° C. with t = 0 and 3 months. For -20 ° C, 2-8 ° C, 25 ° C at t = 0, 1 and 3 months, and once and twice freeze / thaw (-1x and 2xFxTh) at -20 ° C / 25 ° C conditions FIG. 7 presents a table of longer term study results by size exclusion HPLC in Formulation F3. FIG. 5 shows size exclusion HPLC chromatograms for formulations F1, F5, F6, F7, F8, F9 and innovator (control) at t = 0. FIG. 2 shows size exclusion HPLC chromatograms in formulations F1, F5, F6, F7, F8, F9 and innovators after one cycle of freeze / thaw at −20 ° C./25° C. FIG. 4 shows size exclusion HPLC chromatograms for formulations F1, F5, F6, F8 at −20 ° C. and t = 1 month. FIG. 3 shows size exclusion HPLC chromatograms for formulations F1, F3, F5, F6 and F8 at −20 ° C. and t = 3 months. FIG. 6 shows size exclusion HPLC chromatograms for formulations F1, F5, F6, F8 at 2-8 ° C. for t = 1 month. FIG. 3 shows size exclusion HPLC chromatograms for formulations F1, F3, F5, F6 and F8 at 2-8 ° C. and t = 3 months. FIG. 4 shows size exclusion HPLC chromatograms for formulations F1, F5, F6, F8 at 25 ° C. and t = 1 month. FIG. 6 shows chromatograms of size exclusion HPLC for formulations F1, F3, F5, F6, F8 and innovators at 25 ° C. and t = 3 months. FIG. 4 shows size exclusion HPLC chromatograms for formulations F1, F5 and F8 at 25 ° C. and t = 1 month. FIG. 2 shows size exclusion HPLC chromatograms for formulations F1, F3, F5, F8 and innovators at 25 ° C. and t = 3 months. FIG. 2 shows size exclusion HPLC chromatograms for formulations F1, F3, F5 and F8 at 25 ° C. and t = 1 month. FIG. 6 shows chromatograms for size exclusion HPLC on formulations F1, F5, F6 and F8 after 2 cycles of freeze / thaw at −20 ° C./25° C. Size exclusion HPLC chromatograms for formulations F1, F3, F5, F6 and F8 for -20 ° C conditions up to 6 months for formulation F3 and up to 3 months for formulations F1, F5, F6 and F8 It is a figure which shows no outline graph. Peak percentages are measured and expressed (% pre-peak,% main peak and% post peak). Size exclusion HPLC chromatography on Formulas F1, F3, F5, F6 and F8 for Formulas F1, F3, F5, F6 and F8 up to 6 months for Formulation F3 and up to 3 months for Formulations F1, F5, F6 and F8 It is a figure which shows the summary graph of Gram. Peak percentages are measured and expressed (% pre-peak,% main peak and% post peak). Size exclusion HPLC chromatograms for formulations F1, F3, F5, F6 and F8 for 25 ° C. conditions up to 6 months for formulation F3 and up to 3 months for formulations F1, F5, F6 and F8 It is a figure which shows a summary graph. Peak percentages are measured and expressed (% pre-peak,% main peak and% post peak). Size exclusion HPLC chromatograms of formulations F1, F3, F5, F6 and F8 after 1 and 2 cycles of freeze / thaw (1 × and 2 × FxTh) at t = 0 and −20 ° C./25° C. conditions. It is a figure which shows a summary graph. Peak percentages are measured and expressed (% pre-peak,% main peak and% post peak). Bars are shown in the following formulation order: F1, F3, F5, F6 and F8 for each condition (ie t = 0, 1 × FxTh or 2 × FxTh). FIG. 6 is a schematic graph of size exclusion HPLC chromatograms for Formulation F3 at t = 0, 1 month, 3 months and 6 months at −20 ° C., 2-8 ° C. and 25 ° C. storage conditions. FIG. 6 shows a graph containing analysis of cell-based potency assays in all formulations for −20 ° C. conditions at all time points (% relative potency compared to potency of reference standard). FIG. 10 shows a graph containing analysis of cell-based potency assays in all formulations for 25 ° C. conditions at all time points (% relative potency compared to potency of reference standard). FIG. 6 shows a graph containing analysis of cell-based potency assays in all formulations for 50 ° C. conditions at all time points (% relative potency compared to potency of reference standard). Includes analysis of cell-based potency assay (% relative potency compared to reference standard potency) in all formulations for 3 freeze / thaw (−20 ° C./25° C.) and 3 day conditions with agitation It is a figure which shows a graph. The following conditions: After 0 ×, 2 × and 4 × freeze / thaw at −20 ° C., 2-8 ° C., 25 ° C., and −20 ° C./25° C. at time 0, 1 month, 3 months and 6 months FIG. 5 shows a graph containing an analysis of cell-based potency assays in% Formulation F3 (% relative potency compared to potency of reference standard). A data table is presented next to the drawing. Compared to innovators after 3 months at 25 ° C., −20 ° C., 2-8 ° C., after 3 months at 25 ° C. (and 6 months after F3), and after 4 × freeze / thaw at −20 ° C./25° C. FIG. 6 shows a graph containing an analysis of cell-based potency assays (% relative potency compared to that of the reference standard) in the formulations F1, F3, F5, F6 and F8. A data table is presented next to the drawing. FIG. 3 is a bar graph including measured values of pH and osmolality at an initial time. Measure protein concentration (absorbance at 280 nm) at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 freeze / thaw cycles, and 3 days with stirring). FIG. Measure turbidity (absorbance at 330 nm) at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 freeze / thaw cycles, and 3 days with stirring). FIG. FIG. 7 shows invisible particle analysis by HIAC measured using Standards-Duke Scientific Count Cal under all conditions: −20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw and agitation for 3 days. All conditions: SDS-PAGE gel stained with Coomassie when incubated for 3 days with freezing / thawing and stirring 3 times at −20 ° C., 25 ° C., 50 ° C. at time 0 and 14 days. FIG. (A) is the F1 sample and (B) is the F4 sample. FIG. 2 shows size exclusion HPLC chromatograms for all formulations for −20 ° C. conditions at all time points. Peak percentages are measured and shown in the table. FIG. 5 shows size exclusion HPLC chromatograms for all formulations for 25 ° C. conditions at all time points. Peak percentages are measured and shown in the table. FIG. 5 shows size exclusion HPLC chromatograms for all formulations for 3 days conditions with 3 freeze / thaw cycles and agitation. Peak percentages are measured and shown in the table. FIG. 6 shows a graph containing analysis of cell-based potency assays in all formulations for −20 ° C. conditions at all time points (% relative potency compared to potency of reference standard). FIG. 10 shows a graph containing analysis of cell-based potency assays in all formulations for 25 ° C. conditions at all time points (% relative potency compared to potency of reference standard). FIG. 6 shows a graph containing an analysis of cell-based potency assay (% relative potency compared to reference standard potency) in all formulations for 3 days conditions with 3 freeze / thaw cycles and agitation.

Detailed Description of the First Aspect of the Invention The present invention relates to an isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
A salt present at a concentration of 80 mM to 130 mM;
Excipients selected from the group of trehalose and sucrose and combinations thereof;
An aqueous composition, characterized in that neither arginine nor cysteine is present in the composition.

  Preferably, the composition is further characterized in that no free amino acids are present in the composition. For example, this composition does not contain any of arginine, cysteine, proline, glycine, methionine, histidine, serine, valine, lysine, and glutamic acid.

As used herein, the term “composition” or “compositions” refers to a polypeptide that has been prepared such that it is suitable for injection and / or administration to an individual in need thereof. May refer to a formulation (s). “Composition” may also be referred to as “pharmaceutical composition”. In some embodiments, the compositions provided herein are substantially sterile and do not contain any agent that is excessively toxic or infectious to the recipient. Further, as used herein, a solution or aqueous composition is one or more of a solution dissolved in a suitable solvent (eg, water and / or other solvent, eg, an organic solvent) or compatible solvent. It may mean a fluid (liquid) preparation containing a chemical substance. Further, as used herein, the term “about” means the specified value ± 2% of the value, preferably the term “about” means the specified value (± 0%) exactly.

  The composition according to the invention does not contain arginine or cysteine (or preferably any other amino acid such as proline, glycine, methionine, histidine, serine, valine, lysine, glutamic acid) alone or the composition The polypeptide itself contains arginine or cysteine (or preferably any other amino acid such as proline, glycine, methionine, histidine, serine, valine, lysine, glutamic acid, etc.) amino acid residues in its chain. Note that it may be.

In some embodiments, the expressed Fc domain-containing polypeptide is purified by any standard method. When Fc domain-containing polypeptides are produced intracellularly, particulate debris is removed, for example, by centrifugation or ultrafiltration. If the polypeptide is secreted into the medium, the supernatant from such an expression system can be first concentrated using a standard polypeptide concentration filter. Protease inhibitors may be added to inhibit proteolysis, and antibiotics may be included to suppress microbial growth. In some embodiments, the Fc domain-containing polypeptide is used using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis and affinity chromatography, and / or any combination of known or undiscovered purification methods. Purified. For example, protein A can be used to purify Fc domain-containing polypeptides based on human γ1, γ2, or γ4 heavy chains (Lindmark et al., 1983, J. Immunol. Meth. 62: 1-13).

  Fractionation on ion exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on heparin SEPHARSET ™, chromatography on anion or cation exchange resin (eg polyaspartic acid column), isoelectric point Other polypeptide purification methods such as electrophoresis, SDS-PAGE, and ammonium sulfate precipitation may be utilized as needed. Other polypeptide purification methods can be used.

  In preferred embodiments, the salt concentration is 80 mM to 130 mM, preferably 90 mM to 130 mM, such as 105 mM to 130 mM, such as about 90 mM, 100 mM, or 125 mM. The salt concentration (preferably NaCl) is preferably about 90 mM. Regardless of the concentration, the salt is preferably sodium chloride, but potassium chloride, sodium citrate, magnesium sulfate, calcium chloride, sodium hypochlorite, sodium nitrate, mercury sulfide, sodium chromate, magnesium dioxide, etc. The salt may be used. This particular range of salt concentration makes it possible to obtain a composition according to the invention which is stable even at high temperatures up to 50 ° C. In addition, the values in this range are closer to the physiological osmolality in the human body than the values used in the prior art (eg 140 mM), thus providing a composition that is more suitable for use, for example, subcutaneously.

  In another preferred embodiment, the isolated polypeptide is etanercept. The Fc component of etanercept includes the constant heavy chain 2 (CH2) domain, constant heavy chain 3 (CH3) domain and hinge region of human IgG1, but does not include the constant heavy chain 1 (CH1) domain. Etanercept can be produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. Etanercept consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons (Physicians' Desk Reference, 2002, Medical Economics Company Inc.).

  The concentration of the isolated polypeptide is preferably 10 mg / mL to 100 mg / mL, more preferably 20 mg / mL to 60 mg / mL, and still more preferably the concentration is about 25 mg / mL or about 50 mg / mL. The concentration is preferably about 50 mg / mL.

  In another preferred embodiment, the excipient is trehalose in the form of trehalose dihydrate at a concentration of 10 mg / mL to 80 mg / mL, preferably 30 mg / mL to 65 mg / mL, more preferably 60 mg / mL. . In another preferred embodiment, the excipient is sucrose at a concentration of 5 mg / mL to 80 mg / mL, and sucrose is preferably present in the range of 10 mg / mL to 40 mg / mL. In a more preferred embodiment, the sucrose concentration is 10 mg / mL. In another more preferred embodiment, the concentration of sucrose is 34 mg / mL. In another preferred embodiment, the excipient is a combination of sucrose and trehalose, where the concentrations range from 5 mg / mL to 80 mg / mL and 10 mg / mL to 80 mg / mL, respectively. The excipient is preferably sucrose at a concentration of about 34 mg / mL. More preferably, the excipient is sucrose at a concentration of about 10 mg / mL.

The composition according to the invention may further comprise an aqueous buffer. The aqueous buffer is sodium phosphate, potassium phosphate, sodium citrate or potassium citrate, maleic acid,
Ammonium acetate, tris- (hydroxymethyl) -aminomethane (Tris), acetate, succinate, diethanolamine, histidine, or combinations thereof are preferred. In a more preferred embodiment, the aqueous buffer is sodium phosphate. In another more preferred embodiment, the aqueous buffer is succinate. In another more preferred embodiment, the aqueous buffer is histidine. Regardless of whether the buffer is used alone or in combination in the composition, the concentration is preferably in the range of 15 mM to 100 mM, preferably 20 mM to 30 mM. In a preferred embodiment, the concentration is preferably in the range 20 mM to 100 mM, preferably 25 mM to 50 mM. In more preferred embodiments, the concentration is about 22 mM or about 25 mM. In another more preferred embodiment, the concentration is about 50 mM. Preferred buffers are sodium phosphate and succinate buffer, the latter being most preferred with a concentration of about 22 mM (succinate buffer).

  In another embodiment, with or without an aqueous buffer, the composition according to the invention comprises one or more excipients in addition to those already mentioned in the composition (trehalose or sucrose). Further, it may be included. In some embodiments, the concentration of the one or more excipients in the compositions described herein is about 0.001 weight percent to 5 weight percent, and in other embodiments one or more The concentration of the plurality of excipients is about 0.1 weight percent to 2 weight percent. Excipients are known in the art and are made by known methods and are available from commercial suppliers. The excipient is lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, glucose, bovine serum albumin, human serum albumin (SA), recombinant hemagglutinin (HA), dextran, polyvinyl alcohol (PVA), hydroxypropyl Methylcellulose (HPMC), polyethyleneimine, gelatin, polyvinylpyrrolidone (PVP), hydroxyethylcellulose (HEC), polyethylene glycol, ethylene glycol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), proline, L-serine, glutamic acid, alanine, Glycine, lysine, sarcosine, γ-aminobutyric acid, polysorbate 20, polysorbate 80, sodium dodecyl sulfate (SDS), Resolvate, polyoxyethylene copolymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ion, copper ion, calcium ion, manganese ion, magnesium ion, 3-[(3- Collamidopropyl) -dimethylammonio] -1-propanesulfonate (CHAPS), sucrose monolaurate, or combinations thereof are preferred. In a more preferred embodiment, the excipient is polysorbate 20, and in a more preferred embodiment, polysorbate 20 is present at a concentration of 0.1%. In another more preferred embodiment, the excipient is glycine, and in a more preferred embodiment, glycine is present at a concentration of 0.5%.

  In another preferred embodiment, the pH of the composition is between pH 6.0 and pH 7.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, Any pH selected from 6.8 and 6.9 is possible. In a more preferred embodiment, the pH of the composition is about 6.3.

  In a particular embodiment, the composition according to the invention comprises 50 mg / mL etanercept, 25 mM sodium phosphate buffer, 10 mg / mL sucrose and 125 mM sodium chloride, and the pH of the composition is 6.3. .

  In another specific embodiment, the composition according to the invention comprises 50 mg / mL etanercept, 25 mM sodium phosphate buffer, 10 mg / mL sucrose and 100 mM sodium chloride, the composition having a pH of 6.3. It is.

In another specific embodiment, the composition according to the invention comprises 50 mg / mL etanercept and 5
It contains 0 mM sodium phosphate buffer, 60 mg / mL trehalose dihydrate and 0.1% polysorbate 20, and the pH of the composition is about pH 6.2.

  In a further specific embodiment, the composition according to the invention comprises 50 mg / mL etanercept, 25 mM sodium phosphate, 34 mg / mL sucrose and 90 mM sodium chloride, the composition having a pH of 6.3. .

  In a further specific embodiment, the composition according to the invention comprises 50 mg / mL etanercept, 25 mM sodium phosphate, 10 mg / mL sucrose, 90 mM sodium chloride and 0.5% glycine, The pH is 6.3.

  In a further specific embodiment, the composition according to the invention comprises 50 mg / mL etanercept, 22 mM succinate, 10 mg / mL sucrose and 90 mM sodium chloride, and the pH of the composition is 6.3. . Preferably, the composition is free (removed) of additional amino acids (except those contained in etanercept). The composition preferably does not contain any of arginine, cysteine, lysine, proline, glutamic acid, serine and methionine.

  The compositions disclosed herein can be administered parenterally, eg, subcutaneously, intramuscularly, intravenously, intraperitoneally, intracerebral spinal cord, intraarticular, intrasynovial, and / or intrathecally.

  The therapeutic effect of the isolated polypeptide contained in the composition according to the present invention is known in the art and includes rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, granulomatosis, Crohn's disease, chronic obstructive pulmonary disease, Treatments include but are not limited to hepatitis C, endometriosis, asthma, cachexia, psoriasis or atopic dermatitis, or other inflammatory or autoimmune related diseases, disorders or conditions. The composition can be administered in an amount (eg, a therapeutically effective amount) sufficient to treat the disorder (alleviate its symptoms, stop or slow its progression).

  The following examples illustrate the invention and are not to be construed as limiting its scope.

Example Composition Preparation of the First Aspect of the Invention The following composition was prepared by simple mixing:

raw materials:
Engineering Running Material containing 62.5 mg / mL etanercept, 1.2 mg / mL Tris, 40 mg / mL mannitol and 10 mg / mL sucrose (pH 7.4), stored at −20 ° C.

  One lot of Enbrel (R) commercial formulation was used as a control sample (referred to herein as "Enbrel (R)" or "Innovator"). The commercial Enbrel® formulation contains 50 mg / mL etanercept, 25 mM Na phosphate, 25 mM arginine, 100 mM NaCl, and 10 mg / mL sucrose (pH 6.3). .

  Etanercept was used as an internal control in the same formulation as the Enbrel® formulation (50.9 mg / mL etanercept, 25 mM Na phosphate, 25 mM arginine, 100 mM NaCl, 10 mg / mL sucrose. (PH 6.3)). This formulation was called F1.

Candidate formulation:
F2: aqueous formulation of etanercept (49.4 mg / mL etanercept, 25 mM Na phosphate, 100 mM NaCl, 10 mg / mL sucrose (pH 6.3))
F3: aqueous formulation of etanercept (49.5 mg / mL etanercept, 25 mM Na phosphate, 125 mM NaCl, 10 mg / mL sucrose (pH 6.3))
F4: aqueous formulation of etanercept (50.9 mg / mL etanercept, 50 mM Na phosphate, 60 mg / mL trehalose dihydrate (pH 6.2), 0.1% polysorbate 20)
F5: aqueous formulation of etanercept (50.0 mg / mL etanercept, 25 mM Na phosphate, 90 mM NaCl, 35 mg / mL sucrose (pH 6.3))
F6: aqueous formulation of etanercept (50.0 mg / mL etanercept, 25 mM Na phosphate, 90 mM NaCl, 10 mg / mL sucrose, 0.5% (5 mg / mL) glycine (pH 6.3))
F7: aqueous formulation of etanercept (50.0 mg / mL etanercept, 28 mM histidine / HCl, 90 mM NaCl, 10 mg / mL sucrose, 6 mg / mL glycine, pH 6.3)
F8: aqueous formulation of etanercept (50.0 mg / mL etanercept, 22 mM succinate, 90 mM NaCl, 10 mg / mL sucrose (pH 6.3)). A succinic acid buffer was prepared using 22 mM succinic acid, and the pH was adjusted to 6.3 by adding NaOH.

Example 1
Fluorescence emission spectra and static light scattering of endogenous proteins Fluorescence emission spectra of endogenous proteins excited at 266 nm and static light scattering data at both 266 nm and 473 nm were acquired. Each sample was loaded into a micro cuvette array (MCA) and placed in Optim 1000 to reveal the difference in colloidal and conformational stability. In this study, the temperature of the thermal gradient experiment was increased from 15 ° C. to 95 ° C. every 1 ° C., and the samples were held at each temperature for 60 seconds to achieve thermal equilibration. In the isothermal experiment, the temperature was held at 62 ° C., held for 60 seconds between measurements, and the sample was measured 200 times repeatedly.

  The time for irradiating the sample with 266 nm and 473 nm laser sources is called exposure time. The choice of exposure time depends on many factors such as the intensity of the fluorescence emission and the ease of photobleaching of the sample. An exposure time of 1 second was used in all these samples.

  In conjunction with changing the exposure time, it is possible to change the size of the physical slit that controls the amount of light entering the detector. Increasing the size of this aperture increases the measured fluorescence signal but reduces the spectral resolution of the instrument.

  The analysis performed by Optim 1000 includes two sequential levels of primary and secondary. Optim 1000 software provides automatic primary and secondary analysis. As with any automated data fitting software, great care must be taken to ensure that the input data is of good quality so that the automated function is reflected in reliable results. All results are confirmed manually by skilled analysts.

The primary analysis extracts spectral parameters from raw fluorescence and light scattering data:
Optim can provide primary level information such as a predicted wavelength (also referred to as centroid average) generally used by scientific papers by using a mathematical function. This examines the average emission wavelength (or center of mass) and is a good approach to remove any noise in the spectral data.
The intensity of the scattered light is calculated from the integrated intensity (Rayleigh scattered UV excitation light) of 260 nm to 270 nm. Scattering efficiency is highly dependent on wavelength, so if the wavelength is short, light is more efficiently scattered by molecules in solution. The 266 nm laser scattering is a very sensitive probe for small changes in average molecular mass.

  In this study, we investigated the thermal denaturation of antibodies by using the fluorescence intensity ratio between 350 nm and 330 nm, and measured the heat-induced aggregation of samples by using the scattered light intensity from 266 nm and 473 nm lasers. .

The secondary analysis takes the parameters of the primary analysis and determines the sample melting temperature “T _m ” and aggregation start temperature “T _agg ” if they are present. The melting temperature is determined as the inflection point of the primary data plotted as a function of temperature.

  The aggregation start temperature is determined as the temperature at which the scattered light intensity increases beyond the threshold for data noise. From the measured minimum temperature, each measured scattered light intensity value is added to the data set of all values measured so far. At each data point, as the analysis proceeds, a linear fit is applied to determine the goodness of fit. If the data deviates significantly from the straight line (where significance is determined by data noise), this is defined as the aggregation start temperature. If not, proceed to the next data point in the data set and test again for this deviation. This method is robust to test against a variety of proteins and conditions. In extreme situations where large agglomerates are formed and precipitation occurs, the light scattering signal may actually decrease if the particles in suspension move away from the focal volume of the incident laser. However, the initial onset is reproducibly detected if any precipitation occurs later.

  For all static light scattering data, all data points are included, regardless of whether the sample appears to precipitate out of solution. The same sample in different replicates may or may not precipitate, but in each case the initiation of the aggregation process is reproducible.

Conclusion Both T _agg and T _onset data between all samples were found to be very similar.
In F1 buffer, the product was found to have a fluorescent T _onset of 63.7 ± 0.3 ° C. and a T _agg of 66.8 ± 0.3 ° C.
In F2 buffer, the product was found to have a fluorescent T _onset of 63.2 ± 0.1 ° C. and a T _agg of 65.9 ± 0.1 ° C.
In F3 buffer, the product was found to have a fluorescent T _onset of 63.4 ± 0.3 ° C. and a T _agg of 65.6 ± 0.4 ° C.
In F4 buffer, the product was found to have a fluorescent T _onset of 63.3 ± 0.1 ° C. and a T _agg of 64.8 ± 0.1 ° C.
In F5 buffer, the product was found to have a fluorescent T _onset of 64.5 ± 0.4 ° C. and a T _agg of 63.0 ± 0.6 ° C.
In F6 buffer, the product was found to have a fluorescent T _onset of 63.9 ± 0.5 ° C. and a T _agg of 64.5 ± 0.2 ° C.
In F7 buffer, the product was found to have a fluorescent T _onset of 61.0 ± 0.7 ° C. and a T _agg of 63.6 ± 0.1 ° C.
In F8 buffer, the product was found to have a fluorescent T _onset of 64.0 ± 0.0 ° C. and a T _agg of 66.2 ± 0.8 ° C.
The Enbrel® innovator itself was found to have a fluorescent T _onset of 63.4 ± 0.1 ° C. and a T _agg of 65.6 ± 0.1 ° C.

  Thus, the data show a high degree of similarity in both colloidal and conformational stability between all samples.

  FIG. 1 shows the results for formulations F1, F5, F6, F7, F8 and innovators (control), the trend being F5> F8> F6> F1> Enbrel®> F7.

An isothermal experiment was performed after the thermal gradient experiment. Analysis and review of thermal gradient results suggests that all samples have a T _agg value of about 64 ° C., so 62 ° C., ie, just below T _agg , but the conformational change and A temperature close enough to undergo colloidal changes was chosen for the isothermal experiment.

The T _onset values found for fluorescence are 63.2 ° C. to 63.7 ° C., the average is 63.4 ° C., and the standard deviation is relatively low at 0.3 ° C., which indicates that five samples (F1 A high degree of comparability between F4 and Enbrel (R) liquid formulations was shown.

  The stability of all samples can also be considered almost equivalent.

Example 2
Short-term stress stability study approach A short-term (two-week) stability study was conducted to evaluate possible formulations before conducting longer-term studies. Further long-term stability studies up to 6 months were conducted on the F3 formulation, and long-term stability studies up to 3 months were conducted on the F5, F6 and F8 formulations.

  Nine formulations were tested:

  Stability of each formulation at t = 0, 3, 7, and 14 days after exposure to two high temperatures (25 ° C. and 50 ° C.) and one real-time temperature in addition to agitation and freeze-thaw stress evaluated.

  For F3 formulation, at 0, 1 month, 3 months and 6 months in addition to freeze thaw stress from 1, 2 and 4 freeze thaw cycles subjected to -20 ° C. freeze / 25 ° C. thaw The stability after exposure to three temperatures (2-8 ° C., −20 ° C. and 25 ° C.) was evaluated.

  In the case of F5, F6 and F8 formulations, 0, 1 and 3 months in addition to freeze-thaw stress due to one, two and four freeze-thaw cycles subjected to -20 ° C freeze / 25 ° C thaw The stability after exposure to three temperatures (2-8 ° C., −20 ° C. and 25 ° C.) was evaluated.

A panel of 8 analytical assays was used to assess the stability of each formulation.
pH (only t = 0)
Osmolality (only t = 0)
Protein concentration (A280nm)
Turbidity (A330nm)
HIAC
Reduced SDS-PAGE (Coomassie Blue stain)
Size exclusion HPLC (SE-HPLC)
Cell-based efficacy

pH and Osmolality FIGS. 2A and 2B show bar graphs containing measured values of pH and osmolality at initial time. These values measured for all formulations prior to constructing samples at each condition were within the theoretical values for target pH or osmolality.

Protein concentration / A280
FIG. 3A shows protein concentration at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (3 × FzTh), and 3 days with stirring). The measured value (absorbance at 280 nm) is shown. The data obtained was kept within the target value range and assay variability range for all samples at all time points and conditions.

  FIG. 3B shows the time 0, 1, 3 and 6 months and conditions (−20 ° C., 2-8 ° C., 25 ° C., once, twice and four times freeze / thaw (1 X, 2x and 4xFzTh)) measured protein concentration (absorbance at 280 nm). A slight increase in protein concentration from the target value (50 mg / mL) is observed, but still remains within the range of assay variability in all conditions up to 3 months. The data comprising this FIG. 3B is presented in the following table:

  In the table below, formulations F1, F5, F6, F8 and t = 0, and after freezing and thawing at −20 ° C., 2-8 ° C. and 25 ° C., t = 3 months, and −20 ° C./25° C. and 4 cycles The data obtained for the innovator (control, 25 ° C. only t = 0 and t = 3) are summarized. The protein concentration is at or near the target value (50 mg / mL) for all formulations.

  The protein concentration measurements for Formulations F5, F6 and F8 (absorbance at 280 nm) at time = 3 months were kept at the target values in all conditions including F1 (Figure Not shown).

Turbidity / A330
FIG. 4A shows the turbidity at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 freeze / thaws (3 × FzTh), and 3 days with stirring). The measured value (absorbance at 330 nm) is shown. According to this result, a significant increase in turbidity was detected at 50 ° C., and F3 exhibited the lowest increase over time. No significant changes were observed in any formulation at -20 ° C, 25 ° C, freeze thaw or agitation.

  FIG. 4B (1) shows time t = 0, 1 month and 3 months and conditions (−20 ° C., 2-8 ° C., 25 ° C., 1 freeze / thaw (1 × and 2 × FzTh (−20 / 25 ° C.)). )) Shows the measured turbidity (absorbance at 330 nm) for Formulation F3, as seen in Fig. 4B (1), a slight increase in turbidity is observed for 3 months at 25 ° C. The sample subjected to storage was observed, and no change was observed for the sample stored at −20 ° C. and 2-8 ° C. even after 3 months and subjected to two freeze-thaw cycles, as shown in FIG. The data comprising 1) is presented in the following table:

  The table below shows formulations F1, F5, F6, F7, F8, F9, and t after 1 cycle, 2 cycles, and 4 cycles of freeze and thaw at t = 0 and t = 3 months and at −20 ° C./25° C. Summarizes data obtained for innovators (control) at = 0 and 25 ° C. Formulations F1, F5 and F8 showed no major change in turbidity. F6 exhibited the highest turbidity variation when stored at 25 ° C.

  As noted above, no further significant increase in turbidity was observed for Formulation F5, F8 or F1 even after one or three months compared to t = 0 under all conditions (FIG. 4B ( 2)).

HIAC (Liquid Particle Counter)
Method:
A HIAC 9703 Liquid Particle Counting System was used for the experiments. The HIAC consists of a sampler, particle counter and Royco sensor. The Royco sensor can size and count particles from 2 μm to 100 μm. This instrument can count 10000 particles / mL or less.
Sample volume (mL): 0.2
Flow rate mL / min: 10
Number of operations (per sample): 4 (excluding the first operation)

procedure:
The sample was initially analyzed without dilution, but it was found that the sample needed to be diluted to obtain more accurate results due to the high viscosity of the sample.
The sample was left at room temperature for 1 hour.
Samples were diluted 1: 3 with appropriate formulation buffer, degassed (1.5 hours) and mixed carefully before measurement.
Standards-Duke Scientific Count Cal: System suitability was confirmed using EZY-Cal 5 μm and 15 μm particle size control standards. A control was first analyzed to verify the resolution of the sensor.

  FIG. 5A shows HIAC measured using Standards-Duke Scientific Count Cal for all conditions: −20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (3 × FzTh), and 3 days with stirring. Shows invisible particle analysis by.

  As seen in FIG. 5A, a significant increase in the number of invisible particles was measured for F1, F2 and F4 at 50 ° C., and F2 showed the highest increase as early as 7 days.

  No significant changes were observed in any of the formulations after stirring at −20 ° C., 25 ° C., 3 × FzTh or 3 days at room temperature. The F3 formulation showed no change in invisible particles after storage at all conditions and time points compared to the t = 0 control.

  FIG. 5B shows -20 ° C., 2-8 ° C., 25 ° C., 1 and 2 freeze / thaw (−20 ° C./25° C.) at t = 0, 1 month and 3 months using Standards-Duke Scientific Count Cal. Figure 2 shows invisible particle analysis by HIAC for Formulation F3 measured at 1x and 2xFzTh) at ° C. As can be seen in FIG. 5B, a further slight increase in the number of invisible particles is observed for the 25 ° C. condition at 3 months. The −20 ° C. condition shows the largest increase in invisible particles in 3 months. No change is observed after 2-8 ° C. or 2 cycles of freeze-thaw at 3 months after t = 0. In one month, a slight increase in the number of invisible particles was observed at -20 ° C.

  The data comprising this FIG. 5B is presented in the following table:

  5C (1) and (2), using Standards-Duke Scientific Count Cal, t = 0, −20 ° C., 2-8 ° C. at 1 month and 3 months (FIG. 5C (1)), 25 ° C., 1 Formulation measured at 1 time, 2 times, 3 times and 4 times freeze / thaw (1 ×, 2 ×, 3 × and 4 × FzTh at −20 ° C./25° C.) (FIG. 5C (2)) Figure 2 shows invisible particle analysis by HIAC for F1, F3, F5, F6 and F8.

  The data making up this FIG. 5C (1) is presented in the table below:

FIG. 5C (2) shows Standards-Duke Scientific Count.
Freeze / thaw (1 ×, 2 × and 4 × FzTh) at t = 0, t = 1 month and t = 3 months using Cal and once, twice and four times at −20 ° C./25° C. Shows invisible particle analysis by HIAC measured for formulations F1, F5, F6 and F8.

  The data making up this FIG. 5C (2) is presented in the table below:

  As can be seen in FIG. 5C, no significant change in the number of invisible particles was observed for F1, F3, F5, F6 and F8 at 2-8 ° C. 3 months after t = 0. In addition, F1 and F6 worked similarly at 25 ° C., and invisible particles increased over time up to 3 months. F8 has no significant change over time at 25 ° C., indicating the stability of this formulation.

  No significant change in the number of invisible particles was observed for the control sample (innovator product) after 3 months at 25 ° C. The innovator product exhibited the greatest number of particles over time compared to F1, F3, F5, F6 and F8 (see table below).

SDS-PAGE
FIG. 6A shows SDS-stained with Coomassie when incubated for 3 days with all conditions: −20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw and agitation at time 0 and 14 days. PAGE gel is shown. (A) is an F1 sample, (B) is an F2 sample, (C) is an F3 sample, and (D) is an F4 sample.

Significant changes were observed in all formulations for 50 ° C. conditions at all time points, and the 14 day sample was probably covalently modified as evidenced by the additional HMW band present (greater than about 250 kDa). High molecular weight (HMW) species and low molecular weight (LMW) degraded species (less than 50 kDa) that existed as early as 3 days at 50 ° C. for all formulations.

  No changes were observed in any formulation compared to the reference standard for all other conditions and time points.

  FIG. 6B (1) shows Formulation F3 at t = 3 months incubated with 2 freeze / thaw cycles under all conditions: −20 ° C., 2-8 ° C., 25 ° C., −20 ° C./25° C. SDS-PAGE gel stained with Coomassie.

  After 3 months at 25 ° C., changes were observed including the appearance of additional bands at about 100 kDa and about 140 kDa, and an increase in the intensity of LMW (low molecular weight) degradation bands at about 50 kDa and about 30 kDa.

  After two cycles of freeze-thaw (−20 ° C./25° C.), changes including darkening of the bands of about 30 kDa and about 50 kDa were observed.

  FIG. 6B (2) shows Formulation F3 at t = 6 months incubated in all conditions: −20 ° C., 2-8 ° C., 25 ° C., −20 ° C./25° C. with 4 freeze / thaw cycles. SDS-PAGE gel stained with Coomassie.

  Changes are observed in F3 after 6 months at 25 ° C., including the appearance of an additional band at about 100 kDa and an increase in the intensity of the LMW degradation bands at about 50 kDa and about 30 kDa.

  FIG. 6C shows an SDS-PAGE gel stained with Coomassie for formulations F5, F6 and F7, and innovator (control) after a single freeze / thaw at t = 0 and −20 ° C./25° C. conditions. Indicates.

  Formulations F5, F6, F7 and innovator (control) at t = 0 are equivalent to the reference standard.

  Formulations F5, F6, F7 after one cycle of freezing and thawing at -20 ° C / 25 ° C are equivalent to the reference standard.

  FIG. 6D shows an SDS-PAGE gel stained with Coomassie for Formulations F8, F9 and F1, and innovator (control) after a single freeze / thaw at t = 0 and −20 ° C./25° C. conditions. Indicates.

  Formulations F8, F9, F1 after one cycle of freeze-thaw at t = 0 and −20 ° C./25° C. are equivalent to the reference standard.

  FIG. 6E (1) shows the Coomassie for Formulations F1 and F5 after 2 cycles of freeze / thaw at −20 ° C., 2-8 ° C. and 25 ° C. and −20 ° C./25° C. conditions at t = 1 month. Shows an SDS-PAGE gel stained with

  Formulations F1 and F5 at all conditions at 1 month are equivalent to the reference standard.

A slight trace of an additional approximately 100 kDa band for Formulation F5 is shown after 1 month at 25 ° C.

  FIG. 6E (2) shows the Coomassie for Formulations F1 and F5 after 4 cycles of freeze / thaw at −20 ° C., 2-8 ° C. and 25 ° C. and −20 ° C./25° C. conditions at t = 3 months. Shows an SDS-PAGE gel stained with

  These additional bands also show a slight trace of the appearance of very faint bands at about 100 kDa, about 50 kDa and about 30 kDa for F5 after 3 months at 25 ° C compared to F1 after 3 months at 25 ° C. Has been demonstrated.

  FIG. 6F (1) shows Coomassie for Formulations F6 and F8 after two cycles of freeze / thaw at −20 ° C., 2-8 ° C. and 25 ° C., and −20 ° C./25° C. conditions at t = 1 month. Shows an SDS-PAGE gel stained with

  Formulas F6 and F8 at −20 ° C. and 2-8 ° C. after 1 month were found to be equivalent to the reference standard, including 2 cycles of freeze / thaw at −20 ° C./25° C. Yes.

  Formulation F6 after 1 month at 25 ° C. shows almost complete loss of the main band with some additional low molecular weight degradation band traces.

  FIG. 6F (2) shows Coomassie for Formulations F6 and F8 after two cycles of freeze / thaw at −20 ° C., 2-8 ° C. and 25 ° C., and −20 ° C./25° C. conditions at t = 3 months. Shows an SDS-PAGE gel stained with

  Significant changes have been observed including the disappearance of the 150 kD band and the appearance of several LMW degradation bands for F6 after 3 months at 25 ° C. Only a trace of the appearance of very faint bands at about 50 kDa and about 30 kDa is shown in both F6 and F8.

SE HPLC (size exclusion HPLC)
conditions:
Column: TSKGel SuperSW3000 4.6 × 300 mm, 4 μm (Tosoh, 18675) CV = 2.5 mL
Column temperature: 25 ° C
Mobile phase: 0.2 M phosphate buffer (pH 6.8)
Flow rate: 0.35 mL / min Execution time: 20 minutes Sample filling amount: 37.6 μg
Autosampler temperature: 4 ° C

  FIG. 7 shows all conditions for all conditions at all time points: −20 ° C. (7A), 25 ° C. (7B), 50 ° C. (7C), 3 freeze / thaw and 3 days (7D) with stirring. Figure 3 shows the size exclusion HPLC chromatogram in the formulation. Peak percentages are measured and shown in the table.

  Significant changes were observed in all formulations for 50 ° C conditions at all time points, with F2 acting the worst overall with a dramatic increase in pre-peak aggregates as early as 3 days (26.3% and 22.7%). F1 and F3 showed a relatively more gradual increase in pre-peak aggregation after 3 days at 50 ° C. (11.9% and 9.3%, respectively), but after 14 days the pre-peak aggregates for all four formulations Increased by over 50%.

Also, at 25 ° C., a slight change in both the main peak area% and the% pre-peak occurred for all formulations after 7 days, the% pre-peak increased further in 14 days, and F4 as a whole pre- The largest increase in aggregate (0.5%) was shown, and F3 showed the smallest increase in aggregation.

  No significant changes were observed with either formulation when exposed to conditions of stirring and freeze-thawing or storage at -20 ° C for up to 14 days.

  FIG. 7E (1) shows in formulation F3 for −20 ° C., 2-8 ° C., t = 3 months at 25 ° C., and two freeze / thaw (2 × FxTh) conditions at −20 ° C./25° C. The chromatogram of size exclusion HPLC is shown.

  Significant pre-peak aggregation and post-peak degradation has been observed for this formulation exposed to 25 ° C. for 3 months compared to all other conditions.

  FIG. 7E (2) shows in formulation F3 for -20 ° C., 2-8 ° C., t = 6 months at 25 ° C., and 4 freeze / thaws (4 × FxTh) at −20 ° C./25° C. conditions. The chromatogram of size exclusion HPLC is shown.

  Significant pre-peak aggregation and post-peak degradation have been observed for this formulation exposed to 6 months at 25 ° C compared to all other conditions after 6 months and after 4 cycles of freeze-thaw.

  FIG. 7F shows size exclusion HPLC chromatograms at 25 ° C. for t = 0, formulation F3 at 1, 3 and 6 months, and formulation innovator after 3 months at 25 ° C.

  Formulation F3 shows a further increase in pre-peak and post-peak aggregates compared to the 1 and 3 month time points.

  The innovator at 25 ° C. for 3 months shows the overall maximum% pre-peak compared to F3 for all other test conditions including 6 months at 25 ° C.

  FIG. 7G (1) shows the size exclusion HPLC chromatogram for formulation F3 at 25 ° C. at t = 0 and 3 months compared to the innovator at t = 0 (control).

  The innovator at t = 0 (control) as a whole exhibits significantly higher pre-peak aggregates than F3 after 3 months at 25 ° C., but lower post-peak degradation.

  FIG. 7G (2) shows a size exclusion HPLC chromatogram in a blend innovator at 25 ° C. with t = 0 and 3 months.

  For innovators, an increase in both pre-peak aggregates and post-peak degradants has been observed after 3 months at 25 ° C. compared to innovators at t = 0.

  FIG. 7H shows formulations for -20 ° C., 2-8 ° C., t = 0 at 25 ° C., and one and two freeze / thaw (1 × and 2 × FxTh) conditions at −20 ° C./25° C. A table of longer term study results by size exclusion HPLC in F3 is presented.

  Formulation F3 has a significant further increase in pre-peak aggregates (t = 1 month to 0.9% at 25 ° C.) and a slight further increase in post-peak degradation (0% of LMW-1 peak from 1 month). 1% further increase).

  FIG. 7I shows the size exclusion HPLC chromatograms for formulations F1, F5, F6, F7, F8, F9 and innovator (control) at t = 0.

  All these formulations show similar chromatographic profiles at t = 0.

  Formulation F9 at t = 0 exhibits a slightly higher pre-peak than F1, F6, F6, F7 and F8.

  The innovator (control) at t = 0 exhibits significantly higher% pre-peaks and post-peaks compared to F1, F5, F6, F7, F8 and F9 at t = 0.

  FIG. 7J shows size exclusion HPLC chromatograms for formulations F1, F5, F6, F7, F8 and F9 after one cycle of freeze / thaw at −20 ° C./25° C.

  Formulations F1, F5, F6, F7 and F8 are equivalent after one cycle of freeze-thaw, and F9 shows a slightly higher% pre-peak (but no further increase from t = 0).

  The table below shows formulations F1, F5, F6, F7, F8 and F9, and size in innovator (control) after one cycle of freeze / thaw (1 × FxTh) at t = 0 and −20 ° C./25° C. conditions. Longer-term study results by exclusion HPLC are presented.

  The control (innovator) exhibits the largest% pre-peak aggregates at t = 0 compared to F1, F5, F6, F7, F8 and F9.

  FIG. 7K (1) shows size exclusion HPLC chromatograms for formulations F1, F5, F6, F8 at −20 ° C. and t = 1 month.

No significant difference is shown between the formulations after 1 month at -20 ° C storage conditions. Only a few smaller post peaks are observed for Formulation F5.

  FIG. 7K (2) shows the size exclusion HPLC chromatogram for formulations F1, F3, F5, F6 and F8 at −20 ° C. and t = 3 months.

  No significant difference is shown between the formulations for F1, F5, F6 and F8 after 3 months at -20 ° C storage conditions. Higher pre-peaks and post-peaks were observed after 3 months at −20 ° C. for F3 compared to all other formulations.

  FIG. 7L (1) shows a size exclusion HPLC chromatogram for formulations F1, F5, F6, F8 at 2-8 ° C. and t = 1 month.

  No significant difference is shown between the formulations after 1 month at 2-8 ° C storage conditions. Only a few smaller post peaks are observed for Formulation F5.

  FIG. 7L (2) shows size exclusion HPLC chromatograms for formulations F1, F3, F5, F6 and F8 at 2-8 ° C. and t = 3 months.

  No significant difference is shown between the formulations after 3 months at 2-8 ° C storage conditions. Higher pre-peaks and post-peaks were observed after 3 months at 2-8 ° C for F3 compared to all other formulations.

  FIG. 7M (1) shows size exclusion HPLC chromatograms for formulations F1, F5, F6, F8 at 25 ° C. and t = 1 month.

  Dramatic changes have been observed including complete loss of the main peak at F6 after 1 month at 25 ° C., resulting in degradation to the post peak. No significant changes were observed in all other formulations (F1, F5, F8) even after 1 month at 25 ° C.

  FIG. 7M (2) shows size exclusion HPLC chromatograms in formulations F1, F3, F5, F6, F8 and innovators at 25 ° C. and t = 3 months.

  After 3 months at 25 ° C., no significant difference was shown between the formulations for F1, F3, F5, F6, F8, and a slightly smaller post peak was observed for F5. The innovator demonstrates that the largest pre- and post-peaks are observed for F3 after 3 months at 25 ° C. F6 exhibits a dramatic change in profile including complete loss of the main peak.

  FIG. 7N (1) shows a size exclusion HPLC chromatogram for formulations F1, F5 and F8 at 25 ° C. and t = 1 month.

  FIG. 7N (2) shows size exclusion HPLC chromatograms for formulations F1, F3, F5, F8 and innovators at 25 ° C. and t = 3 months.

  There is no significant difference between the F1, F3, F5 and F8 formulations after 3 months at 25 ° C. storage conditions. Innovators show significant pre-peak aggregates and post-peak degradations compared to all other formulations.

  FIG. 7O shows the size exclusion HPLC chromatograms for formulations F1, F3, F5 and F8 at 25 ° C. and t = 1 month.

  Formulation F3 exhibits maximum% pre-peak aggregates after 1 month at 25 ° C.

  FIG. 7P shows size exclusion HPLC chromatograms for formulations F1, F5, F6 and F8 after 2 cycles of freeze / thaw at −20 ° C./25° C.

  No significant differences are shown between the formulations after 2 cycles of freeze-thaw at -20 ° C / 25 ° C. Only a slightly smaller post peak is observed for Formulation F5.

  The table below shows t = 0 at storage conditions of −20 ° C., 2-8 ° C. and 25 ° C., 1 month and 3 months, and 1 cycle, 2 cycles and 4 cycles of freeze / cycle at −20 ° C./25° C. conditions. Longer term results from size exclusion HPLC in Formulation F1 after melting (1 ×, 2 × and 4 × FxTh) are presented.

  The table below shows t = 0 at storage conditions of −20 ° C., 2-8 ° C. and 25 ° C., 1 month and 3 months, and 1 cycle, 2 cycles and 4 cycles of freeze / cycle at −20 ° C./25° C. conditions. Longer term results from size exclusion HPLC in Formulation F5 after melting (1 ×, 2 × and 4 × FxTh) are presented.

The table below shows t = 0 at storage conditions of −20 ° C., 2-8 ° C. and 25 ° C., 1 month and 3 months, and 1 cycle, 2 cycles and 4 cycles of freeze / cycle at −20 ° C./25° C. conditions. Melting (1
(2x and 4xFxTh) after long term study results by size exclusion HPLC in Formulation F6.

  The table below shows t = 0 at storage conditions of −20 ° C., 2-8 ° C. and 25 ° C., 1 month and 3 months, and 1 cycle, 2 cycles and 4 cycles of freeze / cycle at −20 ° C./25° C. conditions. Longer term results by size exclusion HPLC in Formulation F8 after melting (1 ×, 2 × and 4 × FxTh) are presented.

  FIG. 7Q, FIG. 7R and FIG. 7S show the conditions: up to 6 months for formulation F3 and up to 3 months for formulations F1, F5, F6 and F8: −20 ° C. (FIG. 7Q), 2-8 ° C. Figure 2 shows a summary graph of size exclusion HPLC chromatograms for formulations F1, F3, F5, F6 and F8 for (7R) and 25 ° C (7S). Peak percentages are measured and expressed (% pre-peak,% main peak and% post peak).

FIG. 7T shows size exclusion HPLC in formulations F1, F3, F5, F6 and F8 after 1 and 2 cycles of freeze / thaw (1 × and 2 × FxTh) at t = 0 and −20 ° C./25° C. conditions. An outline graph of the chromatogram is shown. Peak percentages are measured and expressed (% pre-peak,% main peak and% post peak). Bars are shown in the following formulation order: F1, F3, F5, F6 and F8 for each condition (ie t = 0, 1 × FxTh or 2 × FxTh).

  The table below presents the results of a longer study with size exclusion HPLC in a t = 0 formulation innovator at 25 ° C. storage conditions.

  The table below shows t = 0, 1 month, 3 months and 6 months at -20 ° C, 2-8 ° C and 25 ° C storage conditions, and 1 cycle, 2 cycles and 4 cycles at -20 ° C / 25 ° C conditions. Presents longer term study results by size exclusion HPLC in Formulation F3 after freezing / thawing (1 ×, 2 × and 4 × FxTh).

  The results are shown in FIG. F3 is a further significant increase in pre-peak aggregates at 6 months (t = 3 months to 1.1% increase at 25 ° C.) and a further slight increase in post-peak degradation (from 3 months to 2 .1% further increase).

Cell-based potency assay approach:
For shorter time points (0, 3, 7, and 14)
Samples were tested in two batches (time points after t = 0 and t = 3 days, and after t = 7 days and t = 14 days).
All samples were tested once by single analysis in a bioassay, except that control samples were tested on each day of the 6 day test day.
Absorbance measurements at A280 nm were taken to determine the exact concentration of the primary dilution and subsequent sample dilution.
The overall assay performance was acceptable. Three of the 106 dose response curves (from 53 plates) needed to have one well at up to two different concentrations masked to meet the inter-well variability assay criteria.
Variability between wells% CV ≦ 20%
Assay window (D / A) ≧ 6
R ² ≧ 0.98

The relative potency of 47 test samples was measured once and the control was measured at 6 different times. The average relative potency of the controls was 100.2% and the 95% CI was 96.9% to 103.6%.
The assay variability (% GCV) for the 6 independent measurements of the control was 3.2%. The low assay variability of this method demonstrated that the relative potency values of the test samples obtained from a single measurement were acceptable.
Based on a single measurement, most of the test samples had a relative potency close to 100% (equivalent to that of the reference standard).
Test samples began to lose potency when stored at high temperature (50 ° C.) for 3 days, with potency decreasing with later time points.

For longer time points (3 and 6 months)
Samples were tested in one batch (including t = 6 months (F3) and t = 3 months (all other samples and conditions)).
All samples were tested once in a bioassay by one analyst. The reference standard used is E16 ADS Lot DC-4168-85.
Absorbance measurements at A280 nm were taken to determine the exact concentration of the primary dilution and subsequent sample dilution.
The overall assay performance was acceptable. All dose response curves (12 dose response curves from 6 plates) meet the well-to-well variability assay criteria without masking any wells. The assay acceptance criteria specified in TME 0498-01 are as follows:
Well-to-well variability% CV ≦ 20%
Assay window (D / A) ≧ 6
R ² ≧ 0.98
The assay window for dose response curves in the assay ranged from about 4 to 4.5. All important parameters (A, B, C and D) of the dose response curve are within the normal range of historical data. It has previously been found that the smaller assay window (> 3) did not include assay accuracy and therefore the results of this assay were acceptable.

  In this case, the data was analyzed using Softmax Pro v5.2 to verify assay acceptance criteria and mask wells as needed.

Cell-based bioassay results:
FIG. 8 shows all conditions for all conditions at all time points: −20 ° C. (8A), 25 ° C. (8B), 50 ° C. (8C), 3 freeze / thaw and 3 days (8D) with stirring. Figure 2 shows a graph containing an analysis of cell-based potency assays in formulations (% relative potency compared to potency of reference standard).

Differences in potency (compared to the potency of the reference standard) were detected in all formulations at 50 ° C., all test samples lost potency as early as 3 days, and significantly increased by 14 days storage at 50 ° C. Increased.

  F3 showed the highest efficacy after 14 days at 50 ° C., maintaining a relative efficacy of 42.2%.

  The relative potency for all formulations was kept close to 100% at -20 ° C, 25 ° C and 50 ° C in addition to the conditions of freeze-thawing and room temperature agitation.

  FIG. 8E shows the following conditions: 1 at −20 ° C., 2-8 ° C., 25 ° C., and −20 ° C./25° C. at t = 0, t = 1 month, t = 3 months and t = 6 months. Figure 2 shows a graph containing analysis of cell-based potency assay in Formulation F3 after x, 2x and 4x freeze / thaw (% relative potency compared to potency of reference standard). A data table is presented next to the drawing.

  Formula F3 after 4 cycles of freeze-thaw at all conditions up to 6 months and at −20 ° C./25° C. showed% relative potency comparable to the reference standard and remained within assay variability (≦ 20%). The minimum% relative potency value (89.5%) was measured for F3 after 3 months at 25 ° C.

  FIG. 8F shows 4 × at −20 ° C., 2-8 ° C., 3 months at 25 ° C. (plus 6 months at F3), and −20 ° C./25° C. compared to innovators after 3 months at 25 ° C. 1 shows a graph including analysis of cell-based potency assays (% relative potency compared to reference standard potency) in formulations F1, F3, F5, F6 and F8 after freeze / thaw. A data table is presented next to the drawing.

  No significant difference in% relative potency was observed between F1, F3, F5 and F8 compared to innovators in all conditions. All samples had relative potency equivalent to the reference standard. F6 after 3 months at 25 ° C. had no residual efficacy.

  All samples had relative potency equivalent to the reference standard.

  Formulations F5 (50 mM Na phosphate, 90 mM NaCl, 34 mg / mL sucrose (pH 6.3)) and F8 (50 mM succinate / NaOH, 90 mM NaCl, 10 mg / mL sucrose (pH 6.3)) ) Is identified as a lead formulation based on the overall stability and relative potency as a whole as shown in the table above, and thus F8 is equal to or more than F1 (innovator liquid formulation) It has been shown to work well and better than the F3 and F6 formulations.

Item 1 of the first aspect of the present invention An isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
A salt present at a concentration of 90 mM to 130 mM;
Excipients selected from the group of trehalose and sucrose or combinations thereof;
An aqueous composition comprising: no arginine or cysteine present in the composition.
2. Item 2. The composition according to Item 1, wherein the salt concentration is 105 mM to 130 mM.
3. 3. The composition according to item 1 or 2, wherein the salt concentration is 125 mM.
4). 4. The composition according to any one of items 1 to 3, wherein the salt is sodium chloride.
5). Item 5. The composition according to any one of Items 1 to 4, wherein the isolated polypeptide is etanercept.
6). 6. The composition according to any one of items 1 to 5, wherein the excipient is trehalose at a concentration of 20 mg / mL to 80 mg / mL.
7). Item 7. The composition according to any one of Items 1 to 6, wherein the excipient is sucrose at a concentration of 5 mg / mL to 80 mg / mL.
8). Item 8. The composition according to any one of Items 1 to 7, further comprising an aqueous buffer.
9. Aqueous buffer is sodium phosphate, potassium phosphate, sodium or potassium citrate, succinic acid, maleic acid, ammonium acetate, tris- (hydroxymethyl) -aminomethane (Tris), acetate, diethanolamine, histidine, or Item 9. The composition according to Item 8, which is a combination thereof.
10. Item 10. The composition according to item 8 or 9, wherein the aqueous buffer is present at a concentration of 20 mM to 100 mM.
11. The composition according to any one of items 1 to 10, further comprising one or more excipients.
12 Excipients are lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, glucose, bovine serum albumin, human serum albumin, recombinant hemagglutinin, dextran, polyvinyl alcohol, hydroxypropyl methylcellulose (HPMC), polyethyleneimine, gelatin, Polyvinyl pyrrolidone (PVP), hydroxyethyl cellulose (HEC), polyethylene glycol, ethylene glycol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), proline, L-serine, glutamic acid, alanine, glycine, lysine, sarcosine, γ-aminobutyric acid , Polysorbate-20, polysorbate-80, sodium dodecyl sulfate, polysorbate, polyoxyethylene Polymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ion, copper ion, calcium ion, manganese ion, magnesium ion, 3-[(3-colamidopropyl)- The composition according to item 11, which is dimethylammonio] -1-propanesulfonate, sucrose monolaurate, or a combination thereof.
13. 13. The composition according to any one of items 1 to 12, wherein the pH of the composition is pH 6.0 to pH 7.0.
14 Item 14. Any one of Items 1-13, comprising 50 mg / mL etanercept, 25 mM sodium phosphate buffer, 10 mg / mL sucrose, and 125 mM sodium chloride, wherein the pH of the composition is 6.3. Composition.
15. Items 1-13, comprising 50 mg / mL etanercept, 50 mM sodium phosphate buffer, 60 mg / mL trehalose dihydrate and 0.1% polysorbate 20, wherein the pH of the composition is 6.2. The composition as described in any one of these.
16. Item 14. Any one of Items 1-13, comprising 50 mg / mL etanercept, 25 mM sodium phosphate buffer, 90 mM sodium chloride, and 24 mg / mL sucrose, wherein the composition has a pH of 6.3. Composition.
17. 50 mg / mL etanercept and 25 mM sodium phosphate buffer and 90 m
14. The composition according to any one of items 1 to 13, comprising M sodium chloride, 10 mg / mL sucrose and 5 mg / mL glycine, wherein the pH of the composition is 6.3.
18. 14. Composition according to any one of items 1 to 13, comprising 50 mg / mL etanercept, 22 mM succinate, 90 mM NaCl, and 10 mg / mL sucrose, wherein the pH of the composition is pH 6.3. object.

Second aspect of the invention A second aspect of the invention is a stable aqueous solution free of some selected amino acids and some selected salts suitable for storage of polypeptides containing TNFR: Fc. It relates to a pharmaceutical composition.

  The second aspect of the present invention is based on the finding that aqueous formulations according to the technical features described below can result in increased protein stability at high temperatures above 5 ° C.

Therefore, the second aspect of the present invention is
An isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
Mono- or disaccharides;
An aqueous buffer,
An aqueous composition comprising arginine, cysteine, sodium chloride, potassium chloride, sodium citrate, magnesium sulfate, calcium chloride, sodium hypochlorite, sodium nitrate, mercury sulfide, sodium chromate And an aqueous composition characterized in that none of the salt selected from magnesium dioxide is included.

Detailed Description of the Second Aspect of the Invention The present invention relates to an isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
Mono- or disaccharides;
An aqueous buffer,
An aqueous composition comprising arginine, cysteine, sodium chloride, potassium chloride, sodium citrate, magnesium sulfate, calcium chloride, sodium hypochlorite, sodium nitrate, mercury sulfide, sodium chromate And an aqueous composition characterized in that none of the salt selected from magnesium dioxide is included.

  As used in this second aspect of the invention, the term “composition” comprises a polypeptide comprising a polypeptide prepared such that it is suitable for injection and / or administration to an individual in need thereof. (May be multiple types). “Composition” may also be referred to as “pharmaceutical composition”. In some embodiments, the compositions provided herein are substantially sterile and do not contain any agent that is excessively toxic or infectious to the recipient. Furthermore, when used in this second aspect of the invention, the solution or aqueous composition is dissolved in a suitable solvent (eg water and / or other solvent, eg organic solvent) or a mixture of compatible solvents. It can mean a fluid (liquid) preparation containing a species or chemicals. Further, as used herein, the term “about” means the specified value ± 2% of the value, preferably the term “about” means the specified value (± 0%) exactly.

  The composition according to this second aspect of the invention does not contain arginine or cysteine alone or is added to the composition, but the polypeptide itself contains arginine or cysteine amino acid residues in its chain Please note that you may.

  In some embodiments, the expressed Fc domain-containing polypeptide is purified by any standard method. When Fc domain-containing polypeptides are produced intracellularly, particulate debris is removed, for example, by centrifugation or ultrafiltration. If the polypeptide is secreted into the medium, the supernatant from such an expression system can be first concentrated using a standard polypeptide concentration filter. Protease inhibitors may be added to inhibit proteolysis, and antibiotics may be included to suppress microbial growth. In some embodiments, the Fc domain-containing polypeptide is used using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis and affinity chromatography, and / or any combination of known or undiscovered purification methods. Purified. For example, protein A can be used to purify Fc domain-containing polypeptides based on human γ1, γ2, or γ4 heavy chains (Lindmark et al., 1983, J. Immunol. Meth. 62: 1-13).

  Fractionation on ion exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on heparin SEPHARSET ™, chromatography on anion or cation exchange resin (eg polyaspartic acid column), isoelectric point Other polypeptide purification methods such as electrophoresis, SDS-PAGE, and ammonium sulfate precipitation may be utilized as needed. Other polypeptide purification methods can be used.

  In a preferred embodiment of this second aspect of the invention, the isolated polypeptide is etanercept. The Fc component of etanercept includes the constant heavy chain 2 (CH2) domain, constant heavy chain 3 (CH3) domain and hinge region of human IgG1, but does not include the constant heavy chain 1 (CH1) domain. Etanercept can be produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. Etanercept consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons (Physicians' Desk Reference, 2002, Medical Economics Company Inc.).

  The concentration of the isolated polypeptide is preferably 10 mg / mL to 100 mg / mL, more preferably 20 mg / mL to 60 mg / mL, and still more preferably the concentration is about 25 mg / mL or about 50 mg / mL.

  In another preferred embodiment of this second aspect of the invention, the monosaccharide or disaccharide is selected from trehalose and sucrose. Trehalose is preferably present in the form of trehalose dihydrate at a concentration of 20 mg / mL to 80 mg / mL, more preferably 40 mg / mL to 60 mg / mL, and even more preferably 60 mg / mL. Sucrose is preferably present at a concentration of 10 mg / mL to 80 mg / mL, more preferably 40 mg / mL to 60 mg / mL, and even more preferably 60 mg / mL. In another preferred embodiment of the second aspect of the invention, the excipient is a combination of sucrose and trehalose.

  In another preferred embodiment of this second aspect of the invention, the aqueous buffer of the composition comprises sodium phosphate, potassium phosphate, sodium citrate or potassium citrate, maleic acid, ammonium acetate, tris- (hydroxy Selected from methyl) -aminomethane (Tris), acetate, diethanolamine, and combinations thereof. Whether the buffer is used alone or in combination in the composition, the concentration is preferably 20 mM to 150 mM, more preferably about 50 mM, and a more preferred aqueous buffer is phosphate. Sodium.

In another embodiment of this second aspect of the invention, the composition according to the invention may further comprise one or more excipients. In some embodiments of this second aspect of the invention, the concentration of the one or more excipients in the compositions described herein is about 0.001 weight percent to 5 weight percent, In other embodiments of this second aspect of the invention, the concentration of the one or more excipients is between about 0.1 weight percent and 2 weight percent. Excipients are known in the art and are made by known methods and are available from commercial suppliers. The excipients are lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, glucose, bovine serum albumin, human serum albumin (SA), recombinant hemagglutinin (HA), dextran, polyvinyl alcohol (PVA), hydroxypropyl Methyl cellulose (HPMC), polyethyleneimine, gelatin, polyvinylpyrrolidone (PVP), hydroxyethyl cellulose (HEC), polyethylene glycol, ethylene glycol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), proline, L-serine, glutamic acid, alanine, Glycine, lysine, sarcosine, γ-aminobutyric acid, polysorbate 20, polysorbate 80, sodium dodecyl sulfate (SDS), Resolvate, polyoxyethylene copolymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ion, copper ion, calcium ion, manganese ion, magnesium ion, 3-[(3- Collamidopropyl) -dimethylammonio] -1-propanesulfonate (CHAPS), sucrose monolaurate, or combinations thereof are preferred. In a more preferred embodiment, the excipient is polysorbate 20, and in a more preferred embodiment, polysorbate 20 is present at a concentration of 0.1%.

  In another preferred embodiment of this second aspect of the invention, the pH of the composition is between pH 6.0 and pH 7.0, 6.1, 6.2, 6.3, 6.4, 6.5. , 6.6, 6.7, 6.8 and 6.9 are possible. In a more preferred embodiment, the pH of the composition is about 6.2.

  In a particular embodiment of this second aspect of the invention, the composition comprises 50 mg / mL etanercept, 50 mM sodium phosphate buffer and 60 mg / mL trehalose dihydrate, The pH is pH 6.2.

  In a particular embodiment of this second aspect of the invention, the composition comprises 50 mg / mL etanercept, 50 mM sodium phosphate buffer, 60 mg / mL trehalose dihydrate and 0.1% polysorbate 20 And the pH of the composition is pH 6.2.

  In a particular embodiment of this second aspect of the invention, the composition comprises 50 mg / mL etanercept, 50 mM sodium phosphate buffer and 60 mg / mL sucrose, wherein the pH of the composition is pH 6. 2.

  In certain embodiments of this second aspect of the invention, the composition comprises 50 mg / mL etanercept, 50 mM sodium phosphate buffer, 60 mg / mL sucrose, and 0.1% polysorbate 20; The pH of the composition is pH 6.2.

  The composition disclosed in this second aspect of the specification may be administered parenterally, for example subcutaneously, intramuscularly, intravenously, intraperitoneally, intracerebral spinal, intraarticularly, intrasynovial and / or intrathecally. it can.

The therapeutic effect of the isolated polypeptide contained in the composition according to this second aspect of the invention is known in the art and includes rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, granulomatosis, Crohn's disease, Treatment of chronic obstructive pulmonary disease, hepatitis C, endometriosis, asthma, cachexia, psoriasis or atopic dermatitis, or other inflammatory or autoimmune related diseases, disorders or conditions, It is not limited to these. The composition can be administered in an amount (eg, a therapeutically effective amount) sufficient to treat the disorder (alleviate its symptoms, stop or slow its progression).

  The following examples illustrate the second aspect of the present invention and are not to be construed as limiting its scope.

Example Composition Preparation of the Second Aspect of the Invention The following composition was prepared by simple mixing:

raw materials:
Engineering Running Material containing 62.5 mg / mL etanercept, 1.2 mg / mL Tris, 40 mg / mL mannitol and 10 mg / mL sucrose (pH 7.4), stored at −20 ° C.

Reference formulation (referred to herein as “Enbrel”):
A lot of Enbrel (R) commercial formulation was used as a control sample. The commercial formulation contains 50 mg / mL etanercept, 25 mM Na phosphate, 25 mM arginine, 100 mM NaCl, and 10 mg / mL sucrose (pH 6.3).

Candidate formulation:
F1: Etanercept was used as an internal control in the same formulation as the Enbrel® formulation (50.9 mg / mL etanercept, 25 mM Na phosphate, 25 mM arginine, 100 mM NaCl, 10 mg / mL Of sucrose (pH 6.3)).
F2: aqueous formulation of etanercept (49.4 mg / mL etanercept, 25 mM Na phosphate, 100 mM NaCl, 10 mg / mL sucrose (pH 6.3))
F3: aqueous formulation of etanercept (49.5 mg / mL etanercept, 25 mM Na phosphate, 125 mM NaCl, 10 mg / mL sucrose (pH 6.3))
F4: aqueous formulation of etanercept (50.9 mg / mL etanercept, 50 mM Na phosphate, 60 mg / mL trehalose dihydrate (pH 6.2), 0.1% polysorbate 20)

  In some experiments, a commercial lot of Enbrel® is also used as a reference (see above).

Example 1
Fluorescence emission spectra and static light scattering of endogenous proteins Fluorescence emission spectra of endogenous proteins excited at 266 nm and static light scattering data at both 266 nm and 473 nm were acquired. Each sample was loaded into a micro cuvette array (MCA) and placed in Optim 1000 to reveal the difference in colloidal and conformational stability. In this study, the temperature of the thermal gradient experiment was increased from 15 ° C. to 95 ° C. every 1 ° C., and the samples were held at each temperature for 60 seconds to achieve thermal equilibration. In the isothermal experiment, the temperature was held at 62 ° C., held for 60 seconds between measurements, and the sample was measured 200 times repeatedly.

  The time for irradiating the sample with 266 nm and 473 nm laser sources is called exposure time. The choice of exposure time depends on many factors such as the intensity of the fluorescence emission and the ease of photobleaching of the sample. An exposure time of 1 second was used in all these samples.

  In conjunction with changing the exposure time, it is possible to change the size of the physical slit that controls the amount of light entering the detector. Increasing the size of this aperture increases the measured fluorescence signal but reduces the spectral resolution of the instrument.

  The analysis performed by Optim 1000 includes two sequential levels of primary and secondary. Optim 1000 software provides automatic primary and secondary analysis. As with any automated data fitting software, great care must be taken to ensure that the input data is of good quality so that the automated function is reflected in reliable results. All results are confirmed manually by skilled analysts.

The primary analysis extracts spectral parameters from raw fluorescence and light scattering data:
Optim can provide primary level information such as a predicted wavelength (also referred to as centroid average) generally used by scientific papers by using a mathematical function. This examines the average emission wavelength (or center of mass) and is a good approach to remove any noise in the spectral data.
The intensity of the scattered light is calculated from the integrated intensity (Rayleigh scattered UV excitation light) of 260 nm to 270 nm. Scattering efficiency is highly dependent on wavelength, so if the wavelength is short, light is more efficiently scattered by molecules in solution. The 266 nm laser scattering is a very sensitive probe for small changes in average molecular mass.

  In this study, we investigated the thermal denaturation of antibodies by using the fluorescence intensity ratio between 350 nm and 330 nm, and measured the heat-induced aggregation of samples by using the scattered light intensity from 266 nm and 473 nm lasers. .

The secondary analysis takes the parameters of the primary analysis and determines the sample melting temperature “T _m ” and aggregation start temperature “T _agg ” if they are present. The melting temperature is determined as the inflection point of the primary data plotted as a function of temperature.

  The aggregation start temperature is determined as the temperature at which the scattered light intensity increases beyond the threshold for data noise. From the measured minimum temperature, each measured scattered light intensity value is added to the data set of all values measured so far. At each data point, as the analysis proceeds, a linear fit is applied to determine the goodness of fit. If the data deviates significantly from the straight line (where significance is determined by data noise), this is defined as the aggregation start temperature. If not, proceed to the next data point in the data set and test again for this deviation. This method is robust to test against a variety of proteins and conditions. In extreme situations where large agglomerates are formed and precipitation occurs, the light scattering signal may actually decrease if the particles in suspension move away from the focal volume of the incident laser. However, the initial onset is reproducibly detected if any precipitation occurs later.

  For all static light scattering data, all data points are included, regardless of whether the sample appears to precipitate out of solution. The same sample in different replicates may or may not precipitate, but in each case the aggregation initiation process is reproducible.

Conclusion Both T _agg and T _onset data between all samples were found to be very similar.
In F1 buffer, the product was found to have a fluorescent T _onset of 63.7 ± 0.3 ° C. and a T _agg of 66.8 ± 0.3 ° C.
In F2 buffer, the product was found to have a fluorescent T _onset of 63.2 ± 0.1 ° C. and a T _agg of 65.9 ± 0.1 ° C.
In F3 buffer, the product was found to have a fluorescent T _onset of 63.4 ± 0.3 ° C. and a T _agg of 65.6 ± 0.4 ° C.
In F4 buffer, the product was found to have a fluorescent T _onset of 63.3 ± 0.1 ° C. and a T _agg of 64.8 ± 0.1 ° C.
The Enbrel® innovator itself was found to have a fluorescent T _onset of 63.4 ± 0.1 ° C. and a T _agg of 65.6 ± 0.1 ° C.

  Thus, the data show a high degree of similarity in both colloidal and conformational stability between all samples.

The T _onset values found for fluorescence are 63.2 ° C. to 63.7 ° C., the average is 63.4 ° C., and the standard deviation is relatively low at 0.3 ° C., which indicates that five samples (F1 A high degree of comparability was shown between F4 and Enbrel® liquid formulations.

  The F4 formulation is very conformationally similar to the Enbrel® liquid formulation with respect to conformational and colloidal stability, as shown in all experiments. it is conceivable that.

Example 2
Short-term stress stability study approach A short-term (two-week) stability study was conducted to evaluate possible formulations before conducting longer-term studies.

  Four formulations were tested:

  Stability of each formulation at t = 0, 3, 7, and 14 days after exposure to two high temperatures (25 ° C. and 50 ° C.) and one real-time temperature in addition to agitation and freeze-thaw stress evaluated.

A panel of 8 analytical assays was used to assess the stability of each formulation.
pH (only t = 0)
Osmolality (only t = 0)
Protein concentration (A280nm)
Turbidity (A330nm)
HIAC
Reduced SDS-PAGE (Coomassie Blue stain)
Size exclusion HPLC
Cell-based efficacy

pH and Osmolality FIG. 9 shows a bar graph containing measured values of pH and osmolality at the initial time. These values measured for all formulations prior to constructing samples at each condition were within the theoretical values for target pH or osmolality.

Protein concentration / A280
FIG. 10 shows the protein concentration at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (3 × FzTh), and 3 days with stirring). The measured value (absorbance at 280 nm) is shown. The data obtained was kept within the target value range and assay variability range for all samples at all time points and conditions.

Turbidity / A330
FIG. 11 shows turbidity at all times (0-14 days) and conditions (−20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (3 × FzTh), and 3 days with stirring). The measured value (absorbance at 330 nm) is shown. According to this result, a significant increase in turbidity was detected at 50 ° C., and F3 exhibited the lowest increase over time. No significant changes were observed in any formulation at -20 ° C, 25 ° C, freeze thaw or agitation.

HIAC (Liquid Particle Counter)
Method:
A HIAC 9703 Liquid Particle Counting System was used for the experiments. The HIAC consists of a sampler, particle counter and Royco sensor. The Royco sensor can size and count particles from 2 μm to 100 μm. This instrument can count 10000 particles / mL or less.

procedure:
The sample was initially analyzed without dilution, but it was found that the sample needed to be diluted to obtain more accurate results due to the high viscosity of the sample.
The sample was left at room temperature for 1 hour.
Samples were diluted 1: 3 with appropriate formulation buffer, degassed (1.5 hours) and mixed carefully before measurement.
Standards-Duke Scientific Count Cal: System suitability was confirmed using EZY-Cal 5 μm and 15 μm particle size control standards. A control was first analyzed to verify the resolution of the sensor.

  FIG. 12 shows all conditions using Standards-Duke Scientific Count Cal: −20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw (3 × FzTh), and HIAC measured in 3 days with stirring. Shows invisible particle analysis by.

  A significant increase in the number of invisible particles was measured for F1, F2 and F4 at 50 ° C., and F2 showed the highest increase as early as 7 days.

  No significant changes were observed in any of the formulations after stirring at −20 ° C., 25 ° C., 3 × FzTh or 3 days at room temperature.

  F4 showed no change in invisible particles after storage at all conditions and time points compared to the t = 0 control.

SDS-PAGE
FIG. 13 shows all conditions: SDS-stained with Coomassie at time 0 and 14 days, incubated at −20 ° C., 25 ° C., 50 ° C., 3 times freeze / thaw and agitation for 3 days. PAGE gel is shown. (A) is the F1 sample and (D) is the F4 sample.

  Significant changes were observed in all formulations for 50 ° C. conditions at all time points, and the 14 day sample was probably covalently modified as evidenced by the additional HMW band present (greater than about 250 kDa). High molecular weight (HMW) species and low molecular weight (LMW) degraded species (less than 50 kDa) that existed as early as 3 days at 50 ° C. for all formulations.

  No changes were observed in any formulation compared to the reference standard for all other conditions and time points.

SE HPLC (size exclusion HPLC)
conditions:
Column: TSKGel SuperSW3000 4.6 × 300 mm, 4 μm (Tosoh, 18675) CV = 2.5 mL
Column temperature: 25 ° C
Mobile phase: 0.2 M phosphate buffer (pH 6.8)
Flow rate: 0.35 mL / min Execution time: 20 minutes Sample filling amount: 37.6 μg
Autosampler temperature: 4 ° C

  FIG. 14 shows the size exclusion HPLC in all formulations for the following conditions at all time points: −20 ° C. (14A), 25 ° C. (14B), 3 freeze / thaw and 3 days (14C) with stirring. The chromatogram of is shown. Peak percentages are measured and shown in the table.

  The 25 ° C condition resulted in slight changes in both the% main peak area and the% prepeak after 7 days for all formulations, the% prepeak increased further in 14 days and F4 increased the maximum prepeak aggregates (. This increase is not significant enough to be considered.

  No significant changes were observed with either formulation when exposed to conditions of stirring and freeze-thawing or storage at -20 ° C for up to 14 days.

Cell-based potency assay approach:
Samples were tested in two batches (time points after t = 0 and t = 3 days, and after t = 7 days and t = 14 days).
All samples were tested once in a bioassay by one analyst, except that control samples were tested on each day of the 6 day test day.
Absorbance measurements at A280 nm were taken to determine the exact concentration of the primary dilution and subsequent sample dilution.
The overall assay performance was acceptable. Three of the 106 dose response curves (from 53 plates) needed to have one well at up to two different concentrations masked to meet the inter-well variability assay criteria.
Variability between wells% CV ≦ 20%
Assay window (D / A) ≧ 6
R ² ≧ 0.98

The relative potency of 47 test samples was measured once and the control was measured at 6 different times. The average relative potency of the controls was 100.2% and the 95% CI was 96.9% to 103.6%.
The assay variability (% GCV) for the 6 independent measurements of the control was 3.2%. The low assay variability of this method demonstrated that the relative potency values of the test samples obtained from a single measurement were acceptable.
Based on a single measurement, most of the test samples had a relative potency close to 100% (equivalent to that of the reference standard).

Cell-based bioassay results:
FIG. 15 shows cell-based in all formulations for all conditions at all time points: −20 ° C. (15A), 25 ° C. (15B), 3 freeze / thaw and 3 days (15C) with agitation. 1 shows a graph containing analysis of potency assay (% relative potency compared to potency of reference standard).

  As shown in FIG. 15, the relative potency for all formulations was kept close to 100% at −20 ° C. and 25 ° C. in addition to the conditions of freeze thawing and stirring at room temperature.

Item 1 of the second aspect of the present invention An isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
Mono- or disaccharides;
An aqueous buffer,
An aqueous composition comprising arginine, cysteine, sodium chloride, potassium chloride, sodium citrate, magnesium sulfate, calcium chloride, sodium hypochlorite, sodium nitrate, mercury sulfide, sodium chromate And an aqueous composition characterized by not containing any salt selected from magnesium dioxide.
2. 2. The composition of claim 1, wherein the isolated polypeptide is etanercept.
3. Item 3. The composition according to Item 1 or 2, wherein the monosaccharide or disaccharide is selected from trehalose and sucrose, and combinations thereof.
4). Item 4. The composition according to Item 3, wherein trehalose is present at a concentration of 20 mg / mL to 80 mg / mL.
5). Item 4. The composition according to Item 3, wherein the sucrose is present at a concentration of 10 mg / mL to 80 mg / mL.
6). The aqueous buffer is selected from sodium phosphate, potassium phosphate, sodium citrate or potassium citrate, maleic acid, ammonium acetate, tris- (hydroxymethyl) -aminomethane (tris), acetate, diethanolamine, or combinations thereof The composition according to any one of items 1 to 5, wherein
7). Item 7. The composition according to Item 6, wherein the aqueous buffer is present at a concentration of 20 mM to 150 mM.
8). The composition according to any one of items 1 to 7, further comprising one or more excipients. 9. The excipients are lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, glucose, bovine serum albumin, human serum albumin, recombinant hemagglutinin, dextran, polyvinyl alcohol, hydroxypropyl methylcellulose (HPMC), polyethyleneimine, gelatin, Polyvinyl pyrrolidone (PVP), hydroxyethyl cellulose (HEC), polyethylene glycol, ethylene glycol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), proline, L-serine, glutamic acid, alanine, glycine, lysine, sarcosine, γ-aminobutyric acid , Polysorbate-20, polysorbate-80, sodium dodecyl sulfate, polysorbate, polyoxyethylene Polymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ion, copper ion, calcium ion, manganese ion, magnesium ion, 3-[(3-colamidopropyl)- The composition according to item 8, which is dimethylammonio] -1-propanesulfonate, sucrose monolaurate, or a combination thereof. 10. The composition according to any one of items 1 to 9, wherein the pH of the composition is pH 6.0 to pH 7.0.
11. Item 11. The item according to any one of Items 1 to 10, comprising 50 mg / mL etanercept, 50 mM sodium phosphate buffer and 60 mg / mL trehalose dihydrate, wherein the pH of the composition is pH 6.2. Composition.
12 Item 11. The composition according to any one of Items 1 to 10, comprising 50 mg / mL etanercept, 50 mM sodium phosphate buffer, and 60 mg / mL sucrose, wherein the pH of the composition is pH 6.2.
13. Items 1-10, comprising 50 mg / mL etanercept, 50 mM sodium phosphate buffer, 60 mg / mL trehalose dihydrate, and 0.1% polysorbate 20, wherein the pH of the composition is pH 6.2. The composition as described in any one of these.
14 Any of items 1-10, comprising 50 mg / mL etanercept, 50 mM sodium phosphate buffer, 60 mg / mL sucrose, and 0.1% polysorbate 20, wherein the pH of the composition is pH 6.2. The composition according to item.

Claims (17)

An isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
A salt present at a concentration of 80 mM to 130 mM;
Sodium and / or potassium phosphate buffer, present in a concentration of 20 mM to 30 mM;
Sucrose, an excipient present at a concentration of 34 mg / mL to 80 mg / mL;
An aqueous composition comprising: no arginine or cysteine present in the composition.   The composition of claim 1, wherein the concentration of the salt is 90 mM.   The composition according to claim 1 or 2, wherein the salt is sodium chloride.   The composition according to any one of claims 1 to 3, wherein the isolated polypeptide is etanercept. An isolated polypeptide that is an extracellular ligand binding portion of a human p75 tumor necrosis factor receptor fused to the Fc region of human IgG1;
A salt present at a concentration of 80 mM to 130 mM, but not present at a concentration of 100 mM, and an aqueous buffer that is a succinate buffer;
Excipients selected from the group of trehalose and sucrose or combinations thereof;
An aqueous composition comprising: free amino acids present in the composition.   6. The composition of claim 5, wherein the salt concentration is 90 mM.   The composition according to claim 5 or 6, wherein the salt is sodium chloride.   The composition according to any one of claims 5 to 7, wherein the isolated polypeptide is etanercept.   The composition according to any one of claims 5 to 8, wherein the excipient is sucrose present at a concentration of 5 mg / mL to 80 mg / mL.   The composition according to any one of claims 5 to 9, wherein the aqueous buffer is present at a concentration of 15 mM to 100 mM.   The composition of claim 10, wherein the aqueous buffer is present at a concentration of 20 mM to 30 mM.   The composition of claim 10, wherein the aqueous buffer is present at a concentration of 50 mM.   The composition according to any one of claims 1 to 12, further comprising one or more excipients.   The excipient is lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, glucose, bovine serum albumin, human serum albumin, recombinant hemagglutinin, dextran, polyvinyl alcohol, hydroxypropyl methylcellulose (HPMC), polyethyleneimine, gelatin , Polyvinylpyrrolidone (PVP), hydroxyethylcellulose (HEC), polyethylene glycol, ethylene glycol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), proline, L-serine, glutamic acid, alanine, glycine, lysine, sarcosine, γ-amino Butyric acid, Polysorbate-20, Polysorbate-80, Sodium dodecyl sulfate, Polysorbate, Polyoxyethyl Copolymer, potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, zinc ion, copper ion, calcium ion, manganese ion, magnesium ion, 3-[(3-colamidopropyl) -Dimethylammonio] -1-propanesulfonate, sucrose monolaurate, or a combination thereof.   The composition according to any one of claims 1 to 14, wherein the pH of the composition is pH 6.0 to pH 7.0.   16. Any one of claims 5-11 and 13-15, comprising 50 mg / mL etanercept, 22 mM succinate, 90 mM NaCl, and 10 mg / mL sucrose, wherein the pH of the composition is pH 6.3. The composition according to item.   16. The composition of claims 1-4 and 13-15, comprising 50 mg / mL etanercept, 25 mM sodium phosphate buffer, 90 mM sodium chloride, and 34 mg / mL sucrose, wherein the pH of the composition is pH 6.3. The composition according to any one of the above.

Images